Terrapeutics Pharma
Drug Discovery Platform focused on soil bacteria producing drugs to tackle undruggable targets.
Company Overview
Snapshot
Founded in January 2022 by Eddie Sadan and Ariel Werman, Terrapeutics Pharma operates with 1–10 employees. The company has raised $2.5M across three funding rounds, with Peregrine Ventures participating as an investor.
Business overview
Terrapeutics Pharma is a Health Tech & Life Sciences company focused on discovering novel therapeutic solutions from soil-based microorganisms. The company utilizes its proprietary discovery platform, AIM-N (Activated Induction of Metabolites in Nature), to identify small molecules that can target 'undruggable' targets, primarily Protein-Protein Interactions (PPIs). By disrupting natural soil environments with engineered microorganisms, Terrapeutics Pharma aims to force residents to produce small molecules against predefined drug targets. Its lead discovery program is focused on pan KRAS inhibitors for cancer treatment, serving the pharmaceutical and life sciences industries.
Strategic signal
In March 2022, Terrapeutics Pharma announced a cooperation agreement with the Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) to co-develop natural products for new drugs. This partnership is significant as it validates Terrapeutics' technology for screening and selecting microorganisms against challenging drug targets like antibiotic-resistant bacteria and oncogenic RAS, signaling strong potential for advancing drug discovery in critical therapeutic areas.
Log in to access full profile ›Company Intelligence Q&A
- What is Terrapeutics Pharma's core technology?
- Terrapeutics Pharma's core technology is its AIM-N (Activated Induction of Metabolites in Nature) discovery platform, which unlocks the potential of soil-based microorganisms to produce novel small molecules targeting 'undruggable' Protein-Protein Interactions (PPIs).
- When was Terrapeutics Pharma founded and by whom?
- Terrapeutics Pharma was founded in January 2022 by Eddie Sadan and Ariel Werman.
- What is Terrapeutics Pharma's lead discovery program focused on?
- Terrapeutics Pharma's lead discovery program is focused on pan KRAS inhibitors, which target a protein driving 25% of cancers.
- What significant partnership did Terrapeutics Pharma announce in 2022?
- In March 2022, Terrapeutics Pharma signed a cooperation agreement with the Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) to co-develop novel antibiotics and RAS inhibitors for the treatment of incurable cancers.